Key result
Pharmacokinetic modeling supports lean body mass over standard dosing for 5-fluorouracil to reduce interpatient variability.
Why the study?
Does an individual patient data model-based meta-analysis improve the characterization of intravenous 5-fluorouracil population pharmacokinetics?
Does an individual patient data model-based meta-analysis improve the characterization of intravenous 5-fluorouracil population pharmacokinetics?
Aggregating individual patient data enables building more generalizable population pharmacokinetic models for 5-fluorouracil, highlighting the potential of lean body mass-based and model-informed precision dosing.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Briki et al. (2026) studied this question. Population pharmacokinetic modeling of 5-fluorouracil demonstrated that standard body surface area dosing leaves substantial interpatient variability, supporting lean body mass-based strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: